Allergic rhinitis (AR) is induced by an immunoglobulin E (IgE)-mediated reaction in the
allergen-sensitized subjects, affecting 10% to 40% of the world population. AR could be
divided into two kinds, perennial AR and seasonal AR (SAR).
In recent years, biologics have become promising drugs for allergic diseases. The efficacy
and safety of Omalizumab in treating SAR have been well proven by previous studies. However,
the efficacy in preseasonal treatment for SAR has not yet been studied before.